The electromyography devices market has gained the interest of the healthcare industry, owing to a rise in a number of chronic diseases such as muscular dystrophies, distal myopathies, congenital myopathies, myotonic dystrophy, myotonia congenita, primary periodic paralysis, inflammatory muscle diseases, progressive myositis ossificans, metabolic myopathies, neuromuscular junction diseases, spinal muscular atrophy, and hereditary neuropathies. In addition, an increase in the number of geriatric populations suffering from Parkinson's and Alzheimer's disease leads to high adoption of electromyography (EMG) devices, which are expected to significantly boost the growth of the electromyography devices market. However, the high cost of EMG devices restricts the growth of the market. On the contrary, unmet medical demands in developing countries are expected to provide remunerative opportunities for market expansion
North America is expected to witness the highest growth, in terms of revenue, owing to the presence of robust healthcare infrastructure, the presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to a rise in geriatric population that are vulnerable to neuromuscular diseases, unmet medical demands, rise in awareness regarding the use of electromyography devices in diagnosis of neuromuscular diseases, and increase in public–private investments in the healthcare sector.